Dr. Landau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
MUSC
171 Ashley Ave
Charleston, SC 29425
Summary
- Dr. Danny Landau is an oncologist serving as a medical director of hematology telehealth care for the MUSC Health University Medical Center. His role with MUSC involves building a dynamic hematology telehealth program and expanding care throughout the state of South Carolina.
Dr. Landau is also a medical director for ThymeCare. His mission with Thyme is to help educate the team on how to provide the optimal care for our cancer population. ThymeCare and Dr. Landau have a unified vision on alleviating the burden our members have to live with as they battle their disease.
Previously, Dr. Landau worked for the Orlando Health Cancer Institute. In his role there, he served in several capacities including Interim Chair, Section Chief, Lead of GU oncology, and Patient Experience Champion. He was recognized for his work there, being named a Physician Exemplar for the hospital system.
He received his medical degree from University of South Florida Morsani College of Medicine and has been in practice more than12 years. He is experienced in every aspect of medical oncology and hematology but has put a special focus on genitourinary malignances and both benign and malignant blood conditions.
He has several publications and citings. Dr. Landau has participated as a primary investigator of clinical trials that have been published in the New England Journal of Medicine, amongst other prominent journals.
Dr. Landau has also shown a passion for writing. He was written medical papers and non medical papers alike. Dr. Landau has been quoted in magazines such as Newsweek and Readers Digest.
Education & Training
- Orlando HealthFellowship, Hematology and Medical Oncology, 2008 - 2011
- University of South Florida MorsaniResidency, Internal Medicine, 2005 - 2008
- University of South Florida College of MedicineClass of 2005
Certifications & Licensure
- FL State Medical License 2006 - 2025
- ND State Medical License 2024 - 2025
- OH State Medical License 2023 - 2025
- SC State Medical License 2023 - 2025
- ME State Medical License 2023 - 2024
- PA State Medical License 2023 - 2024
- RI State Medical License 2023 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Physician Exemplar Orlando Health, 2015
Clinical Trials
- S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Publications & Presentations
PubMed
- 116 citationsRucaparib or Physician's Choice in Metastatic Prostate Cancer.Karim Fizazi, Josep M Piulats, M Neil Reaume, Peter Ostler, Ray McDermott
The New England Journal of Medicine. 2023-02-23 - 225 citationsOral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos, Boris V. Afanasyev
The New England Journal of Medicine. 2020-12-24 - 1 citationsSystemic causes of non-dermatologic chronic pruritus in the pediatric population and their management: An unexplored areaPooja Gurnani, Tamir Miloh, Jayanthi Chandar, Danny Landau, Fouad Hajjar
Pediatric Dermatology. 2021-09-13
Journal Articles
- https://www.hematologyandoncology.net/supplements/cases-in-the-management-of-nonmetastatic-castration-resistant-prostate-cancer-darolutamide-added-to-leuprolide-in-a-7...landau, Clinical Advances Hematology Oncology
Lectures
- Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Continuing Conversations With the Speakers on Insights into Hematopoietic Stem Cell Origin, Differentiation and Malignancy Provided by Single Cell Approaches61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- The internet bias toward nontraditional first line prostate cancer treatments.2019 ASCO Annual Meeting - 6/1/2019
Authored Content
- With Sickle Cell Management, Treatment Has Become 'Now What?'November 2024
- I Was so Isolated in Medicine, I Couldn't Even Talk About the WeatherSeptember 2024
- You Shouldn't Choose Medicine 'Just Because'August 2024
- The Comedian OncologistJune 2024
- Join now to see all
Press Mentions
- Could a Pro-Oxidant Supplement Help Slow down Prostate Cancer Progression?October 28th, 2024
- Scientists Determine Once and for All if Cell Phones Cause Brain CancerSeptember 15th, 2024
- Moderate Alcohol Consumption Linked to Health Issues for Older AdultsAugust 15th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: